Make an Inquiry
Accelerating Graft-Versus-Host Disease Drug Development

Graft-versus-host disease (GvHD) remains a significant and complex challenge in allogeneic hematopoietic stem cell transplantation, with limited therapeutic options and high unmet medical need. Protheragen is a specialized partner in preclinical drug development, dedicated to advancing innovative therapeutics for GvHD. Leveraging a comprehensive suite of preclinical services—spanning target validation, lead optimization, pharmacology, and IND-enabling studies—Protheragen supports the seamless progression of candidate compounds toward clinical evaluation. Our scientific team brings deep expertise in immunology and GvHD pathophysiology, utilizing advanced in vitro and in vivo models tailored to the disease’s unique mechanisms. Protheragen’s state-of-the-art platforms ensure robust data generation and translational relevance, while rigorous adherence to global regulatory standards underpins every stage of development. With a proven track record in accelerating preclinical pipelines, Protheragen is committed to driving therapeutic breakthroughs in GvHD. Our integrated approach empowers partners to overcome scientific and regulatory hurdles, expediting the delivery of novel, effective treatments to patients in need.

What is Graft-Versus-Host DiseaseTargets for Graft-Versus-Host DiseaseDrug Discovery and Development ServicesWhy Choose Us

What is Graft-Versus-Host Disease

Graft-versus-host disease (GVHD) is a serious immunological complication that primarily occurs after allogeneic hematopoietic stem cell transplantation (HSCT). It arises when immunocompetent donor T lymphocytes recognize recipient antigens as foreign, leading to an immune attack against the host’s tissues. The pathogenesis involves a cascade beginning with tissue injury from conditioning regimens, which releases inflammatory cytokines and activates host antigen-presenting cells. These, in turn, stimulate donor T cells, resulting in their proliferation and differentiation. Activated T cells and recruited effector cells then target organs such as the skin, liver, and gastrointestinal tract, causing further inflammation and tissue damage. Clinically, GVHD presents in acute and chronic forms. Acute GVHD typically manifests within 100 days post-transplant, with symptoms including skin rashes, gastrointestinal disturbances, and liver dysfunction. Chronic GVHD, which arises later, can resemble autoimmune disorders and affect multiple organs, leading to sclerotic skin changes, dry eyes, oral ulcers, and pulmonary or hepatic involvement. Diagnosis is based on clinical assessment, laboratory findings, and confirmation via tissue biopsy. Management includes immunosuppressive and immunomodulatory agents such as corticosteroids, calcineurin inhibitors (tacrolimus, ciclosporin), JAK inhibitors (ruxolitinib), monoclonal antibodies (axatilimab), and cellular therapies (remestemcel-L), tailored according to disease severity and response to initial treatment.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
axatilimab (Rec INN; USAN); axatilimab-csfr 2155851-88-8
img-2109704-99-4911417-87-3-free-base-belumosudil-mesylate-rec-innm-usan belumosudil mesylate (Rec INNM; USAN) 2109704-99-4; 911417-87-3 (free base) C26 H24 N6 O2 . C H4 O3 S 548.613
img-936563-96-1-ibrutinib-rec-inn-usan ibrutinib (Rec INN; USAN) 936563-96-1 C25 H24 N6 O2 440.497
remestemcel-L (USAN) 2137084-64-9
img-1092939-17-7941678-49-5-free-base-ruxolitinib-phosphate-prop-innm-usan ruxolitinib phosphate (Prop INNM; USAN) 1092939-17-7; 941678-49-5 (free base) C17 H18 N6 . H3 O4 P 404.36
abatacept (Rec INN; USAN) 332348-12-6
img-128794-94-5-mycophenolate-mofetil-usan-ban mycophenolate mofetil (USAN; BAN) 128794-94-5 C23 H31 N O7 433.495
img-104987-11-3-fujimycintacrolimus-rec-inn-usan-ban fujimycin; tacrolimus (Rec INN; USAN; BAN) 104987-11-3 C44 H69 N O12 804.018
img-59865-13-3-ciclosporin-rec-inncyclosporincyclosporin-acyclosp ciclosporin (Rec INN); cyclosporin; cyclosporin A; cyclosporine; cyclosporine A 59865-13-3 C62 H111 N11 O12 1202.611
anti-T-lymphocyte globulin

Learn More

Targets for Graft-Versus-Host Disease

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
ATP binding cassette subfamily B member 1 ABCB1
Bruton tyrosine kinase BTK
BMX non-receptor tyrosine kinase BMX
BLK proto-oncogene, Src family tyrosine kinase BLK
CD80 molecule CD80
colony stimulating factor 1 receptor CSF1R
CD86 molecule CD86
FKBP prolyl isomerase 1A FKBP1A
Janus kinase 1 JAK1
Inosine 5'-monophosphate dehydrogenase (IMPDH) (nonspecified subtype)

Graft-versus-host disease (GVHD) is driven by complex immune interactions, with several molecular targets playing pivotal roles in disease pathogenesis. Key targets include costimulatory molecules CD80 and CD86, which are upregulated on antigen-presenting cells and essential for T cell activation through engagement with CD28 and CTLA-4 on T cells. Kinases such as JAK1, JAK2, BTK, and BLK orchestrate cytokine signaling and immune cell activation, directly influencing the proliferation and effector functions of T cells, B cells, and myeloid cells. Additionally, the colony stimulating factor 1 receptor (CSF1R) regulates monocyte and macrophage survival, fueling inflammatory cascades. The calcineurin pathway, involving FKBP1A, PPP3CB, PPP3CC, PPP3R1, and PPP3R2, is central to T cell activation, with calcineurin-mediated NFAT dephosphorylation enabling pro-inflammatory gene transcription. Therapeutically, these targets offer multiple avenues for intervention. Blockade of CD80/CD86 with agents like abatacept and inhibition of JAK kinases with drugs such as ruxolitinib have demonstrated efficacy in reducing GVHD severity. BTK inhibitors (e.g., ibrutinib) are approved for chronic GVHD, and CSF1R inhibitors are in clinical development. Calcineurin inhibitors, including cyclosporine and tacrolimus, remain the standard for GVHD prophylaxis by disrupting T cell activation. The direct involvement of these targets in immune activation and inflammation underpins their value as therapeutic nodes, with ongoing research aiming to refine and personalize treatment strategies, improve patient outcomes, and minimize immunosuppression-related toxicity.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates Graft-versus-Host Disease (GVHD) drug discovery by providing robust, sensitive platforms to evaluate candidate therapies. We employ advanced biochemical, cell-based, and biophysical assays—including ATP, FRET, HTRF, flow cytometry, and surface plasmon resonance—to assess immune cell activation, proliferation, and signaling pathways. Key pharmacological parameters such as IC-50, Kd, Ki, MIC, and MED are measured for comprehensive efficacy, affinity, and mechanism profiling. Our tailored, high-throughput methodologies ensure reproducibility and actionable insights, supporting lead optimization and preclinical decision-making for effective, targeted GVHD therapy development.

Atp Binding Cassette Subfamily B Member 1 Blk Proto-Oncogene, Src Family Tyrosine Kinase
Bmx Non-Receptor Tyrosine Kinase Bruton Tyrosine Kinase
Cd80 Molecule Cd86 Molecule
Colony Stimulating Factor 1 Receptor Fkbp Prolyl Isomerase 1A
Janus Kinase 1 Janus Kinase 2
Peptidylprolyl Isomerase A

Learn More

Why Choose Us

Choosing Protheragen as your partner in Graft-versus-host disease (GvHD) drug development means placing your trust in a team with deep-rooted expertise in this complex therapeutic area. At Protheragen, our highly skilled professionals are dedicated to advancing GvHD research, leveraging years of experience and a thorough understanding of the disease’s unique challenges. Our state-of-the-art technology platforms and robust scientific methodologies ensure that every stage of preclinical development is conducted with precision and efficiency. Protheragen has built a strong track record of reliability, consistently delivering high-quality preclinical drug development services that meet the evolving needs of our clients. We adhere strictly to international quality standards and regulatory requirements, ensuring that all projects are executed with the utmost integrity and compliance. Above all, Protheragen is committed to making a meaningful impact in the field of GvHD therapeutics. We work tirelessly to translate scientific innovation into tangible solutions, supporting our partners every step of the way to bring new hope to patients affected by GvHD.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing drugs for Graft-versus-host disease (GVHD)?

A: GVHD presents unique preclinical research challenges due to its complex immunological mechanisms and the need for relevant animal models that accurately reflect human disease. Developing and validating these models, especially those that represent both acute and chronic GVHD, is critical for assessing therapeutic efficacy and safety. Additionally, the heterogeneity of GVHD manifestations and patient populations requires careful selection of biomarkers and endpoints to ensure translational relevance.

Q: What regulatory considerations are important for preclinical drug development targeting GVHD?

A: Regulatory agencies such as the FDA and EMA require robust preclinical data for GVHD drug candidates, including pharmacology, toxicology, and proof-of-concept efficacy in relevant models. It is essential to design studies in compliance with GLP standards and to address immunogenicity and potential off-target effects. Early engagement with regulatory authorities through pre-IND meetings can help align study designs with expectations and facilitate a smoother transition to clinical development.

Q: What are the technical aspects of preclinical GVHD research that your company specializes in?

A: Our company specializes in the development and implementation of advanced in vivo and in vitro models for GVHD, including humanized mouse models that recapitulate key features of the disease. We offer comprehensive immunophenotyping, cytokine profiling, and histopathological analyses to evaluate therapeutic mechanisms and efficacy. Additionally, we utilize state-of-the-art imaging and biomarker discovery platforms to provide in-depth characterization of drug candidates.

Q: What are the typical timeline and cost considerations for preclinical development of GVHD therapeutics?

A: Preclinical development timelines for GVHD therapeutics typically range from 12 to 24 months, depending on the complexity of the compound and required studies. Costs can vary significantly based on the scope of work, with comprehensive efficacy, pharmacokinetic, and toxicology packages generally ranging from $1 million to $3 million USD. Our team works closely with clients to optimize study designs and timelines, ensuring cost-effective and efficient progression toward IND submission.

Q: What are the key success factors for preclinical drug development in GVHD?

A: Key success factors include the use of validated, translationally relevant disease models, robust study designs that address both efficacy and safety, and early identification of predictive biomarkers. Close collaboration with regulatory authorities and adherence to GLP standards are also critical. Our integrated approach combines scientific expertise, regulatory insight, and advanced technical capabilities to maximize the likelihood of successful advancement into clinical trials.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2025 Protheragen. All rights reserved.